Search IconSearch
December 4, 2023/Cancer/Blood Cancers

Ten ASH Presentations You Don’t Want to Miss

Cleveland Clinic oncologists’ selected abstracts

23-CNR-4221120 ASH 2023 Graphics-CQD

As the premier event for hematology, the American Society of Hematology annual meeting presents more than 7,000 abstracts about cutting-edge science in the field. This year’s event in San Diego, California is being held in person and virtually. Cleveland Clinic Cancer Institute leadership are calling out the below ten abstracts to watch for during the event.

  1. Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Abstract #91, being presented at 9:30AM on 12/9/23.

  1. Decreased Survival Among Patients with Indolent Systemic Mastocytosis: A Population-Level Retrospective Cohort Analysis Using Healthcare Claims Dataset

Abstract #75, being presented at 10:00AM on 12/9/23.

  1. A Syngeneic Murine Model of Antiphospholipid Syndrome (APS) Recapitulates Aspects of Human APS

Abstract #1190, being presented at 5:30-7:30PM on 12/9/23

  1. A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia

Abstract #2097, being presented at 5:30-7:30PM on 12/9/23

  1. Improving Patient Access and Provider Availability in Classical Hematology: The Development of an Advanced Practice Provider Led Virtual Anemia Consult Clinic

Abstract #2298, being presented at 5:30-7:30PM on 12/9/23

  1. Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen (CAR) T-Cell Therapy

Abstract #308, being presented at 4:15PM on 12/9/23

  1. Risk of Therapy-Related Acute Myeloid Leukemia in Adolescent and Young Adults Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry

Abstract #377, being presented at 5:00PM on 12/9/23

  1. Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study

Abstract #540, being presented at 1:15PM on 12/10/23

  1. Final Results of a Phase 1/2 Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma

Abstract #3087, being presented at being presented at 6:00-8:00PM on 12/10/23

  1. A Phase 2 Multicenter Trial of Ruxolitinib to Treat Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation

Abstract #775, being presented at 10:30AM on 12/11/23


Related Articles

Dr. Mukherjee at Cleveland Clinic
April 1, 2024/Cancer/Blood Cancers
Many Patients with “Indolent” Systemic Mastocytosis Experience Rapid Decline and Lower Survival

First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Treating older patients with diffuse large B-cell lymphoma (DLBCL)
January 18, 2024/Cancer/Blood Cancers
Trial for Patients 75 and Older with Diffuse Large B-Cell Lymphoma Helps Address Care Inequities

Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients

CAR T-cell therapy
April 5, 2023/Cancer/Blood Cancers
Insights About CAR T-Cell Therapy

Dispelling myths and sharing practical experiences

CAR T-cell therapy for multiple myeloma
March 13, 2023/Cancer/Blood Cancers
Ide-CEL CAR T-Cell Therapy Effective in Multiple Myeloma Among Patients with Comorbidities

Research indicates strong rationale for expanding trial eligibility criteria

22-CNR-3245747-CQD-Hero-650×450 aplastic anemia
September 13, 2022/Cancer/Blood Cancers
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Retrospective study yields clues to understanding risk of secondary myeloid neoplasms